Why Has the Use of Health Economic Evaluation in Japan Lagged Behind that in Other Developed Countries?
- 1 January 2002
- journal article
- review article
- Published by Springer Nature in PharmacoEconomics
- Vol. 20 (2), 1-7
- https://doi.org/10.2165/00019053-200220002-00001
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Information Barriers to the Implementation of Economic Evaluations in JapanPharmacoEconomics, 2002
- Current Trends in the Use of Pharmacoeconomics and Outcomes Research in EuropeValue in Health, 1999
- Health Care Reform In Japan: The Virtues of Muddling ThroughHealth Affairs, 1999
- The Revised Canadian Guidelines for the Economic Evaluation of PharmaceuticalsPharmacoEconomics, 1999
- Why Medical Care Costs in Japan Have Increased Despite Declining Prices for PharmaceuticalsPharmacoEconomics, 1998
- Critical Appraisal of Pharmacoeconomic Studies in JapanJapanese Journal of Pharmacoepidemiology/Yakuzai ekigaku, 1997
- A Case for the Adoption of Pharmacoeconomic Guidelines in JapanPharmacoEconomics, 1996